Transparancy & ANBI
Transparancy
The Moiré Foundation is officially recognized by the Dutch tax authority as ANBI (Algemeen Nut Beogende Instelling). ANBI translates to Public Benefit Organization (PBO).The Foundation values transparency regarding its objectives, activities and financial policy. This page provides an overview of the foundation’s activities, its plans for the coming period, and how the Moiré Foundation fulfils its ANBI objectives.
Objective
The Moiré Foundation aims to promote scientific and medical research into UGDH syndrome, with a particular focus on developing effective treatments, fostering collaboration and knowledge exchange among relevant parties, and increasing public awareness and knowledge of UGDH syndrome.
The foundation is a non-profit organization and does not aim to generate profit.
Activities since establishment
Since its establishment, the Moiré Foundation has focused on laying the groundwork for achieving its objectives. During this initial phase, the foundation has worked on establishing the organization, developing communication resources, building an international network of researchers and physicians, and developing a strategic research plan for the development of a gene therapy for UGDH syndrome.
These activities have largely been carried out on a voluntary basis by the foundation’s board members and the experts involved. This has established an important organizational and scientific foundation for the further implementation of the foundation’s objectives.
Policy plan
The policy of the Moiré Foundation is based on four pillars:
Scientific research
Facilitating and supporting research into UGDH syndrome and innovative treatments.
Collaboration
Connecting researchers, physicians and other relevant parties to promote international knowledge exchange and collaboration.
Awareness
Increasing knowledge and public awareness of UGDH syndrome.
Fundraising
Securing the financial resources needed to enable research.
In the coming period, the Moiré Foundation will focus on enabling the first preclinical research phase for the development of a gene therapy for UGDH syndrome.
The full policy plan is available for download in Dutch from the Dutch version of this website.